235 related articles for article (PubMed ID: 28258928)
21. Effect of inhaled dry powder mannitol on mucus and its clearance.
Daviskas E; Rubin BK
Expert Rev Respir Med; 2013 Feb; 7(1):65-75. PubMed ID: 23362816
[TBL] [Abstract][Full Text] [Related]
22. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.
Ademhan Tural D; Yalçın E; Emiralioglu N; Ozsezen B; Sunman B; Nayir Buyuksahin H; Guzelkas I; Dogru D; Ozcelik U; Kiper N
Pediatr Pulmonol; 2022 Jan; 57(1):142-151. PubMed ID: 34687284
[TBL] [Abstract][Full Text] [Related]
23. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults.
Gjoerup J; Hilberg O; Bendstrup E
Respirology; 2012 Aug; 17(6):927-32. PubMed ID: 22564014
[TBL] [Abstract][Full Text] [Related]
24. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
25. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis.
Minasian C; Wallis C; Metcalfe C; Bush A
Pediatr Pulmonol; 2008 Nov; 43(11):1078-1084. PubMed ID: 18972410
[TBL] [Abstract][Full Text] [Related]
26. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.
Daviskas E; Anderson SD; Gomes K; Briffa P; Cochrane B; Chan HK; Young IH; Rubin BK
Respirology; 2005 Jan; 10(1):46-56. PubMed ID: 15691238
[TBL] [Abstract][Full Text] [Related]
27. Inhaled mannitol and cystic fibrosis. Unnecessary bronchial irritation.
Prescrire Int; 2014 Apr; 23(148):89-91. PubMed ID: 24860889
[TBL] [Abstract][Full Text] [Related]
28. [Pilot study of amiloride inhalation in children with cystic fibrosis].
Riedler J; Huttegger I
Klin Padiatr; 1992; 204(3):158-62. PubMed ID: 1614182
[TBL] [Abstract][Full Text] [Related]
29. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Elkins MR; Robinson M; Rose BR; Harbour C; Moriarty CP; Marks GB; Belousova EG; Xuan W; Bye PT;
N Engl J Med; 2006 Jan; 354(3):229-40. PubMed ID: 16421364
[TBL] [Abstract][Full Text] [Related]
30. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
31. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM;
Lancet Respir Med; 2014 Jul; 2(7):539-47. PubMed ID: 24836205
[TBL] [Abstract][Full Text] [Related]
32. Inhalation of dry-powder mannitol increases mucociliary clearance.
Daviskas E; Anderson SD; Brannan JD; Chan HK; Eberl S; Bautovich G
Eur Respir J; 1997 Nov; 10(11):2449-54. PubMed ID: 9426077
[TBL] [Abstract][Full Text] [Related]
33. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.
Ratjen F; Davis SD; Stanojevic S; Kronmal RA; Hinckley Stukovsky KD; Jorgensen N; Rosenfeld M;
Lancet Respir Med; 2019 Sep; 7(9):802-809. PubMed ID: 31178421
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
[TBL] [Abstract][Full Text] [Related]
35. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.
Balfour-Lynn IM; Klein NJ; Dinwiddie R
Arch Dis Child; 1997 Aug; 77(2):124-30. PubMed ID: 9301350
[TBL] [Abstract][Full Text] [Related]
36. [Dry powder inhalers in cystic fibrosis].
Steinkamp G
Pneumologie; 2014 Jun; 68(6):378-85. PubMed ID: 24664997
[TBL] [Abstract][Full Text] [Related]
37. Cost Effectiveness of Inhaled Mannitol (Bronchitol
Warren E; Morgan K; Toward TJ; Schwenkglenks M; Leadbetter J
Pharmacoeconomics; 2019 Mar; 37(3):435-446. PubMed ID: 30666534
[TBL] [Abstract][Full Text] [Related]
38. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis.
Daviskas E; Anderson SD; Young IH
Respir Med; 2010 Mar; 104(3):371-7. PubMed ID: 19914814
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
40. Mucus clearance and lung function in cystic fibrosis with hypertonic saline.
Donaldson SH; Bennett WD; Zeman KL; Knowles MR; Tarran R; Boucher RC
N Engl J Med; 2006 Jan; 354(3):241-50. PubMed ID: 16421365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
